Physician profile
Nickolas E Mileos
NPI 1174039101
$4,624.42
in general payments reported to CMS, 2019-2025
21 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.11 · 2022: $1,380 · 2023: $1,207 · 2024: $1,519 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $813.49 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $662.52 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $606.19 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $445.75 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $193.44 | 2021-2023 | Xarelto |
| Amgen INC. | $146.14 | 2022-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $122.03 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $116.82 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.37 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $94.86 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $84.18 | 2024 | Trintellix |
| Exact Sciences Corporation | $76.14 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $75.59 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $59.23 | 2022-2023 | Gvoke Hypopen |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $51.00 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $42.50 | 2024-2025 | Zoryve, Livalo |
| E.R. Squibb & Sons, L.L.C. | $30.27 | 2022 | |
| Boston Scientific Corporation | $27.76 | 2023 | Spaceoar Vue System - 10ml, Rezum Generator |
| Novartis Pharmaceuticals Corporation | $19.56 | 2023 | |
| Ibsa Pharma INC. | $18.62 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolas Mileos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.